IVD Antibody Development Services for MR-proADM

Creative Biolabs is an undisputed global leader in the rapidly emerging market of in vitro diagnostic (IVD) antibodies. With our professional scientists hammering at Creative Biolabs, we offer a full range of customized IVD antibody development services targeting different disease biomarkers. Here, we introduce our IVD antibody development services for MR-proADM marker.

Human Adrenomedullin (ADM), a 52-amino acid ringed peptide with C-terminal amidation, is a member of the calcitonin peptide family. ADM expresses in a variety of tissues and organ systems, for example, renal, cerebrovascular, cardiovascular and pulmonary. It is a strong vasodilating agents and functions in immune regulation, antibiosis and metabolic modulation. ADM indicates inotropic, natriuretic, and diuretic effects, as well as restrains aldosterone formation. It combines with receptors near the site of its generation right away, and thus has a short half-life. ADM has drawn much attention in cardiovascular studies due to its multiple biological activities, such as induction of vasodilation and hypotension, an improvement in glomerular filtration rate (GFR) and a rise in cardiac output. MRproADM, a stable mid-regional (MR) fragment of the ADM precursor, is able to reflect the level of the quickly degraded active ADM peptide. Clinically, MRproADM is generally used on account of its better technical feasibility than that of ADM.

Figure 1. 3D structure of the ADM. MRproADM is a mid-regional (MR) fragment of the ADM precursor, which is commonly used in clinic.

MR-proADM Marker of Coronary Artery Disease

CAD is the blockage or narrowing of the coronary arteries, generally induced by atherosclerosis. Atherosclerosis is the accumulation of cholesterol and fatty deposits (called plaques) on the inner walls of the arteries. These plaques enable to inhibit blood flow to the heart muscle through blocking the artery or by leading to abnormal artery tone and function. Plasma MR-proADM concentrations enable to forecast adverse outcome in patients with myocardial infarction and seem to add information beyond the strong predictor NT-proBNP. Recently, a research has demonstrated that MR-proADM is an independent marker for future cardiovascular events in patients with symptomatic CAD, offering message comparable to N-terminal pro–B-type natriuretic peptide (NT-proBNP) for secondary risk stratification.

Figure 2. Graphs show the MR-proADM, MR-proANP and NT-proANP levels in patients with cardiovascular (CV) events. MR-proADM is a potential biomarker of CAD, and it can be used along with other biomarker for the diagnosis of diseases. (Baldenhofer, G. 2017)

MR-proADM Marker of Community-acquired Pneumonia

CAP is a disease with a great variety of possible outcomes, which means pneumonia contracted by a person with rarely contact with the healthcare system. It may act as a sepsis precursor and with a very high possibility of leading to death in critically ill patients. Risk stratification is essential to CAP patient management to pick the most suitable care setting. Therefore, proper prognostic factors and risk stratification tools in respiratory medicine are extremely needed. More and more evidence has indicated that MR-proADM is a better biomarker contrasted to others for prognostic purposes in CAP, such as procalcitonin. A research also showed that MR-proADM is predictive of elevated complications and higher mortality rates in patients with CAP.

Figure 3. These graphs show the biomarkers and pneumonia severity index (PSI) severity score. MR-proADM is the only one able to distinguish between all different risk classes of PSI. (Bello, S. 2012)

IVD Antibody Development Services Targeting MR-proADM Marker

Antibodies are core elements for antibody-based immunoassays for detecting and quantifying antigens of interest in all kinds of samples such as the serum, urine, tissue preparations, and so on. IVD antibodies are extensively used for disease screening, prognosis, and therapeutic monitoring. With our versatile IVD platform, Creative Biolabs is proud to develop novel anti-proADM antibody from scratch to commercial IVD kit (we can also start with provided antibody candidates). If you are interested in our services, please do not hesitate to contact us for more details.

Reference

1. Bello, S. (2012). “Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.” European Respiratory Journal 39(5), 1144-1155.
2. Baldenhofer, G. (2017). “Mid-regional pro-adrenomedullin (MR-proADM) and mid-regional pro-atrial natriuretic peptide (MR-proANP) in severe aortic valve stenosis: association with outcome after transcatheter aortic valve implantation (TAVI).” Clinical Chemistry and Laboratory Medicine (CCLM) 55(2), 275-283.

For Research Use Only.